0102030405
ʻO Tirzepatide Dual GLP-1 a me GIP Receptor Agonist no ka hoʻokele paona a me ka mana Glycemic
Ka wehewehe kikoʻī
ʻO Tirzepatide kahi lāʻau lapaʻau hou i hoʻohana ʻia no ka hoʻokele paona lōʻihi i nā poʻe maʻi keu me ka momona o nā pākeke a i ʻole nā mea pili i ke kaumaha. He agonist pili i ka glucose o ka glucagon polypeptide (GIP) a me ka glucagon-like peptide-1 (GLP-1) receptors. Ua ʻae ʻia e ka FDA ma 2022, hui pū ʻo tirzepatide i nā hopena o ʻelua proinsulins enteric i loko o kahi mole hoʻokahi, hoʻonui i ka huna ʻana o ka insulin a hoʻemi i nā pae glucagon. Ke ʻimi nei kēia ʻatikala i ke ʻano o ka hana, ka pono lapaʻau, a me ka ʻike palekana o tirzepatide ma ke ʻano he lāʻau hoʻohui no ka pohō kaumaha a hoʻomaikaʻi i ka mana glycemic i nā maʻi me ka maʻi diabetes type 2.
I. Ka hoomaopopo ana ia Tirzepatide:
A. Glucose-dependent agonist o GIP a me GLP-1 receptors
B. Mechanism o ka hana: hoʻonui i ka pae I a me ka pae II i ka huna ʻana o ka insulin, e hōʻemi ana i nā pae glucagon
II. Nā hoʻohana lāʻau lapaʻau a me ka ʻae ʻana o ka FDA:
A. Hōʻike: ʻO ka hoʻokele paona lōʻihi i nā poʻe maʻi keu me ka momona o nā pākeke a i ʻole nā mea pili i ke kaumaha.
B. Adjunctive therapy no ka hoʻomaikaʻi ʻana i ka mana glycemic i nā pākeke me ka maʻi diabetes type 2
ʻO ka ʻae a me ke kūʻai aku ʻana o C. FDA e Eli Lilly ma 2022
III. ʻO ka maikaʻi i ka hoʻokele kaumaha:
A. Hoʻohālikelike kūpono:
Ka pākēneka o ka pohō kaumaha: Nā hui haʻahaʻa (5mg), nā pūʻulu waena (10mg), a me nā hui kiʻekiʻe (15mg).
'Awelika o ka pohō kaumaha ma nā hui like 'ole
Hoʻohālikelike me ka hui placebo
ʻO ka pākēneka o nā kumuhana e loaʻa ana i ka pohō kaumaha ma luna o 20%
B. ʻIke palekana: ʻO ka pinepine o nā hopena ʻino i hoʻohālikelike ʻia me ka hui placebo
C. Hoʻohālikelike me nā lāʻau hoʻemi kaumaha ʻē aʻe:
Orlistat (over-the-counter): Ka ʻokoʻa i nā pākēneka pohō kaumaha
IV. Mechanism of Glycemic Control and Weight Loss:
A. Ka ho'ā 'ana o GLP-1 a me GIP receptors
B. Hoʻopau i ka ʻai a me ka hoʻemi ʻana i ka ʻai
ʻO Tirzepatide, ma ke ʻano he GLP-1 a me GIP receptor agonist, hāʻawi i ka hoʻokele paona kūpono a hoʻomaikaʻi i ka mana glycemic i nā poʻe maʻi me ka momona o nā pākeke a i ʻole nā mea pili i ke kaumaha, a me nā poʻe me ka maʻi diabetes type 2. ʻO kāna hana pili i ka glucose e hoʻonui ai i ka huna ʻana o ka insulin a hoʻemi i ka pae glucagon. Me nā pākēneka pohō kaumaha nui a me kahi ʻōlelo palekana maikaʻi, kū ʻo tirzepatide ma ke ʻano he lāʻau ikaika no ka hoʻokele paona lōʻihi. E hoʻomau ka noiʻi hou a me nā noiʻi lapaʻau e ʻimi i nā pono kūpono a me nā noi o kēia lāʻau hoʻohiki.
I mea e hāʻawi ai i kahi ʻike kālepa maikaʻi aʻe, hiki iā mākou ke hana i ka capsule a me nā huahana wai, e like me kāu mau mea pono.
Hiki iā mākou ke hoʻonohonoho i ka dosage: 500mg/capsule, 550mg/capsule, 600mg/capsule.
Hiki iā mākou ke hoʻopilikino i ka pahu: 60 kapena / ʻōmole, 90 kaʻa / ʻōmole, 120 kaʻa / ʻōmole.
Hiki iā mākou ke hana i nā pūpū capsule a me nā kala: nā pūpū capsule kanu, nā pūpū capsule gelatin.
Hōʻike
